Le Lézard
Classified in: Health
Subjects: MAV, RCL, CFG

Public Advisory - TUMS Peppermint Regular Strength tablets: One lot recalled due to contamination


OTTAWA, ON, Nov. 30, 2022 /CNW/ - Summary

TUMS Peppermint Regular Strength tablets: One lot recalled due to contamination (CNW Group/Health Canada)

Affected products

Product

NPN

Lot

Expiry

TUMS Peppermint Regular Strength (500mg) tablets, packages of three rolls of 12 tablets

01970240

HA7H

August 2027

Issue

GlaxoSmithKline Consumer Healthcare ULC is recalling one lot of TUMS Peppermint Regular Strength tablets after some tablets were found to contain fragments of fibreglass and other material, including paper and aluminum foil. The product is sold in a package of three rolls containing 12 tablets each, and was distributed across Canada starting on October 25, 2022.

TUMS is an antacid indicated for adult use to relieve indigestion and heartburn caused by too much acid in the stomach.

If consumed, the fragments should pass through most people's digestive systems with no concern; however, elderly people and people who have narrow areas in their intestines because of disease or surgery may be at risk of injury.

Health Canada is monitoring the company's recall and will update the public if any new health risks are identified.

What you should do

Alert / recall type: Public Advisory
Category: Health products ? Natural health products 
Published by: Health Canada

Également disponible en français

SOURCE Health Canada


These press releases may also interest you

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...

at 02:30
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...

3 jui 2024
YOUR LEGAL RIGHTS MAY BE AFFECTED There is a proposed settlement in a class-action lawsuit filed against Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, and Warner-Lambert Company LLC (collectively, "Pfizer") and Ranbaxy Inc.,...



News published on and distributed by: